Cour
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Illinois, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
710 Clark St, Evanston, Illinois, 60201,...Website
www.courpharma.comRevenue
$14.8 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About Cour
Explore more
Cour Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cour your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cour has new funding data
Check out if Cour is spiking on competitors!
Product Launch: Get notified when Cour launches new products
Cour, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cour has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cour had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cour
Earning: See what the market has to say on Cour recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Cour as Masked Content
Find 3 more new buyers
Compare Similar Companies to Cour
Compare insights from companies similar to Cour, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cour is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cour is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cour.
Cour financials insights
Gather financial insights about Cour, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Unspecified
$30M
2024
Series A
$105M
2026
Series B
$50M
Cour Tech Stack
A closer look at the technologies used by Cour
Most Recent Scoops
Project
, according to a front-line source in DevOps, is in the midst of initiatives related to quality assurance. The organization is currently evaluating various vendors. Cour is expected to increase contingent workforce to support these efforts. The organization is focused on manufacturing processes in this area.
Quality Assurance, DevOps, Contingent Workforce
Pain Point
Project
, according to a front-line source in DevOps, is planning to remediate challenges related to communication and collaboration. The organization is currently evaluating various vendors.
Pain Point, Collaboration/Web Apps, DevOps, Employee Relations, Unified Communications, Communications
Project
, according to a front-line source in DevOps, is in the midst of initiatives related to communication and collaboration. The organization is focused on cross-functional alignment in this area.
Collaboration/Web Apps, DevOps, Employee Relations, Unified Communications, Communications
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Cour News & Media
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
CHICAGO, March 03, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, today announced positive one-year results from its Phase 2a study evaluating CNP-104 as a potential treatment for patients with Primary Biliary Cholangitis (PBC).COUR Pharma Publishes Peer-Reviewed Data in Science Advances
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune toleranceCOUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CNP-106, an investigational therapy for the treatment of generalized myasthenia gravis (gMG).COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient has been dosed in the Phase 1b/2a clinical trial for CNP-103, a tolerogenic nanoparticle therapy in development to address the underlying autoimmunity associated with type 1 diabetes (T1D).
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cour
Sign Up For FreeTo access detailed company insights
